Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 18.26 SEK -4.85% Market Closed
Market Cap: 852.6m SEK
Have any thoughts about
Moberg Pharma AB (publ)?
Write Note

Moberg Pharma AB (publ)
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Moberg Pharma AB (publ)
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Moberg Pharma AB (publ)
STO:MOB
Additional Paid In Capital
kr921.3m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Additional Paid In Capital
kr3.4B
CAGR 3-Years
22%
CAGR 5-Years
25%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Additional Paid In Capital
kr6.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Additional Paid In Capital
kr690.2m
CAGR 3-Years
0%
CAGR 5-Years
14%
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Additional Paid In Capital
kr5.5B
CAGR 3-Years
85%
CAGR 5-Years
74%
CAGR 10-Years
N/A
No Stocks Found

Moberg Pharma AB (publ)
Glance View

Market Cap
836.9m SEK
Industry
Pharmaceuticals

Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.

MOB Intrinsic Value
0.61 SEK
Overvaluation 97%
Intrinsic Value
Price

See Also

What is Moberg Pharma AB (publ)'s Additional Paid In Capital?
Additional Paid In Capital
921.3m SEK

Based on the financial report for Dec 31, 2023, Moberg Pharma AB (publ)'s Additional Paid In Capital amounts to 921.3m SEK.

What is Moberg Pharma AB (publ)'s Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
10%

Over the last year, the Additional Paid In Capital growth was 10%. The average annual Additional Paid In Capital growth rates for Moberg Pharma AB (publ) have been 10% over the past three years .

Back to Top